Curious Discoveries in Antiviral Drug Development: The Role of Serendipity

Medicinal Research Reviews

Volumn 35, Issue 4, 2015, Pages 698-719

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

ANPs; DdN analogues; HEPT; Serendipity; Suramin; TIBO, Ebola

Indexed keywords

1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 6 [2 (PHOSPHONOMETHOXY)ALKOXY] 2,4 DIAMINOPYRIMIDINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ADEFOVIR; ANTIVIRUS AGENT; PLERIXAFOR; POLYETHYLENE ALANINE; S ADENOSYLHOMOCYSTEINE HYDROLASE INHIBITOR; SURAMIN; TETRAHYDROIMIDAZO[4,5,1 JK][1,4 BENZODIAZEPIN 2(1H)] ONE; TETRAHYDROIMIDAZO[4,5,1 JK][1,4 BENZODIAZEPIN 2(1H)] THIONE; UNCLASSIFIED DRUG; ENZYME INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DNA SEQUENCE; DRUG DEVELOPMENT; HERPES ZOSTER; HERPESVIRIDAE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RETROVIRIDAE; ANIMAL; CHEMISTRY;

ANIMALS; ANTIVIRAL AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS;

EID: 84930581718     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21340     Document Type: Article

References (97)

1. Norrby E. Nobel Prizes and Life Sciences. Singapore: World Scientific Publishing Co, Pte, Ltd; 2010, 317 p.
2. Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P. 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978;272:583-585.
3. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 1977;74:5716-5720.
4. Whitley RJ, Ch'ien LT, Dolin R, Galasso GJ, Alford CA Jr. Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med 1976;294:1193-1199.
5. De Somer P, De Clercq E, Billiau A, Schonne E, Claesen M. Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro. J Virol 1968;2:878-885.
6. De Somer P, De Clercq E, Billiau A, Schonne E, Claesen M. Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo. J Virol 1968;2:886-893.
7. Claes P, Billiau A, De Clercq E, Desmyter J, Schonne E, Vanderhaeghe H, De Somer P. Polyacetal carboxylic acids: A new group of antiviral polyanions. J Virol 1970;5:313-320.
8. De Clercq E, Descamps J, De Somer P, Samyn C, Smets G. Alopecia in laboratory animals induced by a polyampholyte, polyethylene alanine. Experientia 1980;36:1107-1108.
9. Homan ER, Zendzian RP, Busey WM, Rall DP. Loss of hair in experimental animals induced by cyclophosphamide. Nature 1969;221:1058-1059.
10. Temin HM, Mizutani S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 1970;226:1211-1213.
11. Baltimore D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 1970;226:1209-1211.
12. Schlom J, Spiegelman S. Simultaneous detection of reverse transcriptase and high molecular weight RNA unique to oncogenic RNA viruses. Science 1971;174:840-843.
13. De Clercq E. Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett 1979;8:9-22.
14. De Clercq E. Suramin in the treamtent of AIDS: Mechanism of action. Antiviral Res 1987;7:1-10.
15. Mitsuya, H, Popovic, M, Yarchoan, R, Matsushita, S, Gallo, RC, Broder, S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 1984;226:172-174.
16. Chermann JC, Sinoussi FC, Jasmin C. Inhibition of RNA-dependent DNA polymerase of murine oncornaviruses by ammonium-5-tungsto-2-antimoniate. Biochem Biophys Res Commun 1975;65:1229-1236.
17. Rozenbaum W, Dormont D, Spire B, Vilmer E, Gentilini M, Griscelli C, Montagnier L, Barre-Sinoussi F, Chermann JC. Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. Lancet 1985;1:450-451.
18. Broder S, Yarchoan R, Collins JM, Lane HC, Markham PD, Klecker RW, Redfield RR, Mitsuya H, Hoth DF, Gelmann E. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo. Lancet 1985;2:627-630.
19. Rouvroy D, Bogaerts J, Habyarimana JB, Nzaramba D, Van de Perre P. Short-term results with suramin for AIDS-related conditions. Lancet 1985;1:878-879.
20. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-7100.
21. Sanger F. Sequences, sequences, and sequences. Annu Rev Biochem 1988;57:1-28.
22. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977;74:5463-5467.
23. Sanger F, Coulson AR, Friedmann T, Air GM, Barrell BG, Brown NL, Fiddes JC, Hutchison CA 3rd, Slocombe PM, Smith M. The nucleotide sequence of bacteriophage phiX174. J Mol Biol 1978;125:225-246.
24. Sanger F, Coulson AR, Hong GF, Hill DF, Petersen GB. Nucleotide sequence of bacteriophage lambda DNA. J Mol Biol 1982;162:729-773.
25. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2', 3'-dideoxynucleosides. Proc Natl Acad Sci USA 1986;83:1911-1915.
26. Baba M, Pauwels R, Herdewijn P, De Clercq E, Desmyter J, Vandeputte M. Both 2', 3'-dideoxythymidine and its 2', 3'-unsaturated derivative (2', 3'-dideoxythymidi¬nene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun 1987;142:128-134.
27. Lin TS, Schinazi RF, Prusoff WH. Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2', 3'-didehydrothymidine) against human immuno-deficiency virus. Biochem Pharmacol 1987;36:2713-2718.
28. Hamamoto Y, Nakashima H, Matsui T, Matsuda A, Ueda T, Yamamoto N. Inhibitory effect of 2', 3'-didehydro-2', 3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob Agents Chemother 1987;31:907-910.
29. Soudeyns H, Yao XI, Gao Q, Belleau B, Kraus JL, Nguyen-Ba N, Spira B, Wainberg MA. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991;35:1386-1390.
30. Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Dornsife RE, Averett DR, Krenitsky TA. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997;41:1082-1093.
31. Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, Peck A, Sommadossi JP, St Clair M, Wilson J, Furman PA, Painter G, Choi W-B, Liotta DC. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992;36:2423-2431.
32. De Clercq E. Strategies in the design of antiviral drugs. Nat Rev Drug Discov 2002;1:13-25.
33. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-8337.
34. De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 2004;68:2301-2315.
35. De Clercq E, Descamps J, De Somer P, Barr PJ, Jones AS, Walker RT. E-5-(2-Bromovinyl)-2'-deoxyuridine : A potent and selective antiherpes agent. Proc Natl Acad Sci USA 1979;76:2947-2951.
36. Maudgal PC, De Clercq E, Descamps J, Missotten L, De Somer P, Busson R, Vanderhaeghe H, Verhelst G, Walker RT, Jones AS. (E)-5-(2-Bromovinyl)-2'-deoxyuridine in the treatment of experimental herpes simplex keratitis. Antimicrob Agents Chemother 1980;17:8-12.
37. De Clercq E, Degreef H, Wildiers J, De Jonge G, Drochmans A, Descamps J, De Somer P. Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster infections. Brit Med J 1980;281:1178.
38. Desgranges C, Razaka G, Drouillet F, Bricaud H, Herdewijn P, De Clercq E. Regeneration of an antiviral drug (E)-5-(2-bromovinyl)-2'-de¬oxyuridine (BVDU) in vivo. Nucleic Acids Res 1984;12:2081-2090.
39. Nakayama H, Kinouchi T, Kataoka K, Akimoto S, Matsuda Y, Ohnishi Y. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 1997;7:35-43.
40. McGuigan C, Barucki H, Blewett S, Carangio A, Erichsen JT, Andrei G, Snoeck R, De Clercq E, Balzarini J. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J Med Chem 2000;43:4993-4997.
41. Andrei G, Sienaert R, McGuigan C, De Clercq E, Balzarini J, Snoeck R. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob Agents Chemother 2005;49:1081-1086.
42. Pentikis HS, Matson M, Atiee G, Boehlecke B, Hutchins JT, Patti JM, Henson GW, Morris A. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother 2011;55:2847-2854.
43. Migliore M. FV-100: The most potent and selective anti-varicella zoster virus agent reported to date. Antivir Chem Chemother 2010;20:107-115.
44. De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323:464-467.
45. Jones GH, Moffatt JG. The synthesis of 6'-deoxyhomonucleoside-6'-phosphonic acids. J Am Chem Soc 1968;90:5337-5338.
46. Prisbe EJ, Martin JC, McGee DP, Barker MF, Smee DF, Duke AE, Matthews TR, Verheyden JP. Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1, 3-dihydroxy-2-propoxy)methyl]guanine. J Med Chem 1986;29:671-675.
47. De Clercq E, Holý A. Acyclic nucleoside phosphonates : A key class of antiviral drugs. Nature Rev Drug Discov 2005;4:928-940.
48. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
49. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
50. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681.
51. Baba M, Tanaka H, De Clercq E, Pauwels R, Balzarini J, Schols D, Nakashima H, Perno C-F, Walker RT, Miyasaka T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun 1989;165:1375-1381.
52. Miyasaka T, Tanaka H, Baba M, Hayakawa H, Walker RT, Balzarini J, De Clercq E. A novel lead for specific anti-HIV-1 agents: 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine. J Med Chem 1989;32:2507-2509.
53. Baba M, De Clercq E, Tanaka H, Ubasawa M, Takashima H, Sekiya K, Nitta I, Umezu K, Nakashima H, Mori S, Shigeta S, Walker RT, Miyasaka T. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1991;88:2356-2360.
54. Baba M, De Clercq E, Tanaka H, Ubasawa M, Takashima H, Sekiya K, Nitta I, Umezu K, Walker RT, Mori S, Ito M, Shigeta S, Miyasaka T. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol Pharmacol 1991;39:805-810.
55. Debyser Z, Pauwels R, Baba M, Desmyter J, De Clercq E. Common features in the interaction of tetrahydroimidazo[4, 5, 1-jk][1, 4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase. Mol Pharmacol 1992;41:963-968.
56. Debyser Z, Vandamme AM, Pauwels R, Baba M, Desmyter J, De Clercq E. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2', 3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4, 5, 1-jk][1, 4]-benzodiazepin-2(1H)-thione, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. J Biol Chem 1992;267:11769-11776.
57. Baba M, Shigeta S, Yuasa S, Takashima H, Sekiya K, Ubasawa M, Tanaka H, Miyasaka T, Walker RT, De Clercq E. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 1994;38:688-692.
58. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen MAC, De Clercq E, Janssen PAJ. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990;343:470-474.
59. Debyser Z, Pauwels R, Andries K, Desmyter J, Kukla M, Janssen PAJ, De Clercq E. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4, 5, 1-jk][1, 4]benzodiazepin-2(1H)-one and -thione derivatives. Proc Natl Acad Sci USA 1991;88:1451-1455.
60. Pialoux G, Youle M, Dupont B, Gazzard B, Cauwenbergh GF, Stoffels PA, Davies S, de Saint Martin J, Janssen PA. Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex. Lancet 1991;338:140-143.
61. De Wit S, Hermans P, Sommereijns B, O'Doherty E, Westenborghs R, van De Velde V, Cauwenbergh GF, Clumeck N. Pharmacokinetics of R 82913 in AIDS patients: A phase I dose-finding study of oral administration compared with intravenous infusion. Antimicrob Agents Chemother 1992;36:2661-2663.
62. Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koymans L, Vinkers M, Guillemont J, Pasquier E, Kukla M, Ludovici D, Andries K, de Béthune MP, Pauwels R, Das K, Clark AD Jr, Frenkel YV, Hughes SH, Medaer B, De Knaep F, Bohets H, De Clerck F, Lampo A, Williams P, Stoffels P. In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2, 6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005;48:1901-1909.
63. De Clercq E. Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era. Biochem Pharmacol 2012;84:241-248.
64. Yamamoto N, Schols D, De Clercq E, Debyser Z, Pauwels R, Balzarini J, Nakashima H, Baba M, Hosoya M, Snoeck R, Neyts J, Andrei G, Murrer BA, Theobald B, Bossard G, Henson G, Abrams M, Picker D. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents. Mol Pharmacol 1992;42:1109-1117.
65. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003;2:581-587.
66. De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, Balzarini J, Debyser Z, Murrer BA, Schwartz D, Thornton D, Bridger G, Fricker S, Henson G, Abrams M, Picker D. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 1992;89:5286-5290.
67. De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K, Debyser Z, Rosenwirth B, Peichl P, Datema R, Thornton D, Skerlj R, Gaul F, Padmanabhan S, Bridger G, Henson G, Abrams M. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994;38:668-674.
68. Schols D, Esté JA, Henson G, De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35:147-156.
69. Schols D, Struyf S, Van Damme J, Esté JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388.
70. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP. AMD3100, a small-molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72-77.
71. Hatse S, Princen K, Gerlach LO, Bridger G, Henson G, De Clercq E, Schwartz TW, Schols D. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol Pharmacol 2001;60:164-173.
72. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000;44:1667-1673.
73. De Clercq E. The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009;77:1655-1664.
74. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 2010;128:509-518.
75. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hübel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, Dale DC. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-2730.
76. Maziarz RT, Nademanee AP, Micallef IN, Stiff PJ, Calandra G, Angell J, Dipersio JF, Bolwell BJ. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biol Blood Marrow Transplant 2013;19:670-675.
77. Lefrère F, Mauge L, Réa D, Ribeil JA, Dal Cortivo L, Brignier AC, Aoun C, Larghéro J, Cavazzana-Calvo M, Micléa JM. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: Impact on the timing of the apheresis procedure. Transfusion 2013;53:564-569.
78. Tanhehco YC, Vogl DT, Stadtmauer EA, O'Doherty U. The evolving role of plerixafor in hematopoietic progenitor cell mobilization. Transfusion 2013;53:2314-2326.
79. Montgomery JA, Clayton SJ, Thomas HJ, Shannon WM, Arnett G, Bodner AJ, Kion IK, Cantoni GL, Chiang PK. Carbocyclic analogue of 3-deazaadenosine: A novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target. J Med Chem 1982;25:626-629.
80. De Clercq E. John Montgomery's legacy: Carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity. Nucleosides Nucleotides Nucleic Acids 2005;24:1395-1415.
81. Borchardt RT, Keller BT, Patel-Thombre U. Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. J Biol Chem 1984;259:4353-4358.
82. De Clercq E, Montgomery JA. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. Antiviral Res 1983;3:17-24.
83. De Clercq E. Antiviral and antimetabolic activities of neplanocins. Antimicrob Agents Chemother 1985;28:84-89.
84. De Clercq E, Cools M, Balzarini J, Marquez VE, Borcherding DR, Borchardt RT, Drach JC, Kitaoka S, Konno T. Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives. Antimicrob Agents Chemother 1989;33:1291-1297.
85. Tseng CK, Marquez VE, Fuller RW, Goldstein BM, Haines DR, McPherson H, Parsons JL, Shannon WM, Arnett G, Hollingshead M, Driscoll JS. Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J Med Chem 1989;32:1442-1446.
86. De Clercq E, Cools M. Antiviral potency of adenosine analogues: Correlation with inhibition of S-adenosylhomocysteine hydrolase. Biochem Biophys Res Commun 1985;129:306-311.
87. De Clercq E. S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem Pharmacol 1987;36:2567-2575
88. Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000;45:135-147.
89. Bray M, Raymond JL, Geisbert T, Baker RO. 3-Deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice. Antiviral Res 2002;55:151-159.
90. Holý A, Votruba I, Masojídková M, Andrei G, Snoeck R, Naesens L, De Clercq E, Balzarini J. 6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. J Med Chem 2002;45:1918-1929.
91. De Clercq E, Andrei G, Balzarini J, Leyssen P, Naesens L, Neyts J, Pannecouque, C, Snoeck R, Ying C, Hocková D, Holý A. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2, 4-diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 2005;34:331-341.
92. Balzarini J, Pannecouque C, De Clercq E, Aquaro S, Perno CF, Egberink H, Holý A. Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates. Antimicrob Agents Chemother 2002;46:2185-2193.
93. Hocková D, Holý A, Masojídková M, Andrei G, Snoeck R, De Clercq E, Balzarini J. 5-Substituted-2, 4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity. J Med Chem 2003;46:5064-5073.
94. Ying C, Holý A, Hocková D, Havlas Z, De Clercq E, Neyts J. Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities. Antimicrob Agents Chemother 2005;49:1177-1180.
95. Hocková D, Holý A, Masojídková M, Andrei G, Snoeck R, De Clercq E, Balzarini J. Synthesis and antiviral activity of 2, 4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds. Bioorg Med Chem 2004;12:3197-3202.
96. Balzarini J, Schols D, Van Laethem K, De Clercq E, Hocková D, Masojidková M, Holý A. Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2, 4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines. J Antimicrob Chemother 2007;59:80-86.
97. Herman BD, Votruba I, Holy A, Sluis-Cremer N, Balzarini J. The acyclic 2, 4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. J Biol Chem 2010;285:12101-12108.